Date: 2015-03-17
Type of information: Nomination
Compound:
Company: Molecular Partners (Switzerland)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 17, 2015, Molecular Partners announced the appointment of Dr. Andreas Harstrick as Chief Medical Officer (CMO) and new member of the Executive Management Team. Dr. Andreas Harstrick will assume the role as CMO starting May 1, 2015 and in his position he will oversee Molecular Partner’s clinical activities and expand the clinical development team. Dr. Andreas Harstrick brings 28 years of experience in Oncology to the company. He has a track record of designing clinical trials leading to approval of antibody drugs, including Erbitux (cetuximab targeting EGFR) and Cyramza (ramucirumab targeting VEGFR2). Further he has in-depth experience in setting-up clinical oncology teams and he has held several senior executives roles at leading international companies. Andreas has worked for Imclone Systems, Branchburg NJ, where since 2012 he held the position as SVP Medical Sciences and was a member of the Lilly Oncology Program Review Board and Lilly Oncology Business Development Committee. In that position he led the Imclone Medical Sciences Department and was responsible for the medical leadership and strategy for the company’s projects in all geographies. Before that, Dr. Andreas Harstrick held the position as SVP Clinical Operations, Data Sciences and Medical Communications at Imclone where he managed three departments with more than 200 employees and oversaw the clinical development budget of the group. Since 2008, Andreas was part of Imclone’s Management Committee. Prior to moving to the US, Andreas was VP Clinical Development at Imclone International and SVP Global Clinical Development Unit Oncology at Merck Serono, both in Germany. Dr. Andreas Harstrick had spent his medical career at the University Hospital and Cancer Center Hannover Germany, the Roswell Park Cancer Institute, Buffalo NY, as well as the West German Cancer Center, Essen, Germany.
Financial terms:
Latest news:
